PDF(Pubmed)
Abstract：
The genomic characteristics of Peruvian patients with gastric adenocarcinoma from diverse socioeconomic backgrounds were examined in consideration of the possibility that patients from different socioeconomic backgrounds may be exposed to different risk factors. We conducted a prospective pilot study in two Peruvian cities (Lima and Ica). This study enrolled 15 patients from low socioeconomic status (LSES) and 15 patients from medium/high socioeconomic status (MHSES). The genomic profiling of gastric adenocarcinoma samples was done through the FoundationOne CDx platform. We compared the genomic characteristics and the need for targeted therapy and immunotherapy between LSES and MHSES. The genes with higher rates of alterations were TP53 (73.3% vs. 50.0%, P = 0.2635); CDH1 (26.7% vs. 28.6%, P = 1); CDKN2A (20.0% vs. 28.6%, P = 1); KRAS (33.3% vs. 7.1%, P = 0.1686); ARID1A (20.0% vs. 14.3%, P = 1); MLL2 (13.3% vs. 21.4%, P = 1) and SOX9 (33.3% vs. 0.0%, P = 0.0421) in LSES versus HMSES, respectively. There was no significant difference in tumor mutational burden (P = 0.377) or microsatellite status (P = 1). The LSES group had a higher need for targeted therapy or immunotherapy according to gene involvement and alterations. A significant genomic difference exists among patients with gastric adenocarcinoma of different socioeconomic status, which may result in a different need for targeted therapy and immunotherapy.
摘要：
考虑到来自不同社会经济背景的患者可能暴露于不同风险因素的可能性，研究了来自不同社会经济背景的秘鲁胃腺癌患者的基因组特征。我们在秘鲁的两个城市（利马和伊卡）进行了一项前瞻性试点研究。这项研究招募了15名来自低社会经济地位（LSES）的患者和15名来自中/高社会经济地位（MHSES）的患者。胃腺癌样品的基因组分析通过FoundationOneCDx平台进行。我们比较了LSES和MHSES的基因组特征以及对靶向治疗和免疫治疗的需求。改变率较高的基因是TP53(73.3%vs.50.0%,P=0.2635）；CDH1（26.7%vs.28.6%,P=1）；CDKN2A（20.0%vs.28.6%,P=1）；KRAS（33.3%vs.7.1%,P=0.1686）；ARID1A（20.0%vs.14.3%,P=1）；MLL2（13.3%vs.21.4%,P=1）和SOX9（33.3%与0.0%,P=0.0421）在LSES与HMSES中，分别。肿瘤突变负荷（P=0.377）或微卫星状态（P=1）没有显着差异。根据基因参与和改变，LSES组对靶向治疗或免疫疗法的需求更高。不同社会经济地位的胃腺癌患者之间存在显著的基因组差异,这可能导致对靶向治疗和免疫疗法的不同需求。
